CTSA and Charcot-Marie-Tooth disease type 1A: Ctsa, a known biomarker originally identified from skin [15], was comparably expressed in CMT1A and wildtype controls but importantly, PXT3003-2 and PXT3003-3 short-term treated CMT1A rats showed long-lasting dose-dependent treatment effects on the transcriptional level (Fig 4D).